Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

P. Hughes, Timothy; Branford, Susan; L. White, Deborah; Reynolds, John; Koelmeyer, Rachel; F. Seymour, John; Taylor, Kerry; Arthur, Chris; Schwarer, Anthony; Morton, James; Cooney, Julian; F. Leahy, Michael; Rowlings, Philip; Catalano, John; Hertzberg, Mark; Filshie, Robin; K. Mills, Anthony; Fay, Keith; Durrant, Simon; Januszewicz, Henry; Joske, David; Underhill, Craig; Dunkley, Scott; Lynch, Kevin; Grigg, Andrew

doi:10.1182/blood-2008-06-161737

Public

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Shared by NobleBlocks on Nov 15, 2008 • 12:00 AM UTC

Authors:

Timothy P. Hughes

Susan Branford

Deborah L. White

Abstract

Abstract We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for suboptimal response. The estimated cumulative incidences of complete cytogenetic response (CCR) by 12 and 24 months wer...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!